Elvitegravir product-specific bioequivalence guidance

Current effective version

PDF iconAdopted guideline

Reference numberEMA/CHMP/805507/2016
Published10/07/2017
Effective from01/01/2018
KeywordsBioequivalence, generics, elvitegravir
DescriptionThis document provides product-specific guidance on the demonstration of the bioequivalence of elvitegravir.
Abbreviations
  • BCS Classification: Biopharmaceutics Classification System
  • AUC0-t: area under the plasma concentration curve from administration to last observed concentration at time t
  • AUC0-72: area under the plasma concentration curve from administration to last observed concentration at 72 hours
  • Cmax: maximum plasma concentration



Document history

First version
Current version

PDF iconAdopted guideline

PDF iconDraft guideline

Published: 10/07/2017
Effective from: 01/01/2018

Published: 22/12/2016

Related content


How useful was this page?

Add your rating